Evidence map›Paper›PMID 33667294›Full record

ArticleThe Journal of infectious diseases2021

The State of Microbiome Science at the Intersection of Infectious Diseases and Antimicrobial Resistance.

Ryan T Ranallo, L Clifford McDonald, Alison Laufer Halpin, Thomas Hiltke, Vincent B Young

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Frontiers in veterinary science · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ryan T RanalloDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
L Clifford McDonaldDivision of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Alison Laufer HalpinDivision of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Thomas HiltkeDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Vincent B YoungDepartment of Internal Medicine, Division of Infectious Diseases, The University of Michigan Medical School, Ann Arbor, Michigan, USA.
Centers for Disease Control and Prevention · USNational Institutes of Health · USUniversity of Michigan–Ann Arbor · US

Funding

Systems biology of Clostridium difficile infectionU01AI124255 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHLOSS, PATRICK DAVID, YOUNG, VINCENT B · 2016 to 2020
$9.8M
NCEZID CDC HHS U54 CK000481NCEZID CDC HHS U54 CK000607NIAID NIH HHS U01 AI124255
6 · The paper itself

Abstract

Along with the rise in modern chronic diseases, ranging from diabetes to asthma, there are challenges posed by increasing antibiotic resistance, which results in difficult-to-treat infections, as well as sepsis. An emerging and unifying theme in the pathogenesis of these diverse public health threats is changes in the microbial communities that inhabit multiple body sites. Although there is great promise in exploring the role of these microbial communities in chronic disease pathogenesis, the shorter timeframe of most infectious disease pathogenesis may allow early translation of our basic scientific understanding of microbial ecology and host-microbiota-pathogen interactions. Likely translation avenues include development of preventive strategies, diagnostics, and therapeutics. For example, as basic research related to microbial pathogenesis continues to progress, Clostridioides difficile infection is already being addressed clinically through at least 2 of these 3 avenues: targeted antibiotic stewardship and treatment of recurrent disease through fecal microbiota transplantation.

Indexed as

Drug Resistance, MicrobialMicrobiotaAnti-Bacterial AgentsAntimicrobial StewardshipCommunicable DiseasesFecal Microbiota TransplantationHomeostasisHost-Pathogen InteractionsHumansImmunityAnti-Bacterial Agentsantimicrobial resistancehostinfectious diseaseMicrobiotapathogen

Identifiers

PMID33667294
PMCPMC8206797
OpenAlexW3135809785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.